Home Archive
Archive
2018 Volume 39 Issue 1  Published: 2018-01-10
   Next
    Topic
  • Dan-yang ZHOU , Shan MAO
    doi: 10.13683/j.wph.2018.01.001

    The 2017 global initiative for chronic obstructive pulmonary disease (GOLD) has been fully revised in the diagnosis, evaluation and management of chronic obstructive pulmonary disease (COPD) based on the updated comprehensive references. It was issued on November 16th 2016, which was world COPD day. This article interprets the key points of clinic issue in 2017 edition of GOLD reports.

  • Topic
  • Ying SHI , Wei GU
    doi: 10.13683/j.wph.2018.01.002

    The clinical treatment of chronic obstructive pulmonary disease (COPD) has achieve a great progress in recent years. However, regarding to the use of glucocorticoids is still an important issue. Recent clinical studies on eosinophils in COPD have found that the COPD patients with eosinophilia can benefit from glucocorticoids. This review provides a reference for COPD’s clinical diagnosis and its treatment.

  • Topic
  • Jing ZHANG , Shan MAO
    doi: 10.13683/j.wph.2018.01.003

    For bronchial asthma, there are relatively detailed clinical guidelines. However, the clinical attention should be paid to the diagnosis and treatment of the various types of low incidence asthma. This review describes the special type asthma of eight categories, including their definition, pathogenesis, diagnosis and therapy, and provides a reference for clinical doctors.

  • Topic
  • Ying WANG , Wei GU
    doi: 10.13683/j.wph.2018.01.004

    The pathogenesis of chronic obstructive pulmonary disease (COPD) is not completely clarified at present. However, the macrophages constitute a heterogeneous group of innate immune system cells, which have many functions and exist in large amounts in respiratory tract. The recent studies have shown that the macrophages are involved in the pathogenesis of COPD. This review discusses the role of macrophages in the pathogenesis of COPD.

  • Article
  • Yu-li WANG , Yu-hong TANG , Yang SI , Yan-fang ZHANG , Qi ZHU
    doi: 10.13683/j.wph.2018.01.005
    Objective

    To investigate clinical efficacy of the high dose dexamethasone (HD-DXM) combined with recombinant human interleukin-11 (rhIL-11) in the treatment of the adult patients with newly diagnosed primary immune thrombocytopenia (ITP).

    Methods

    The medical records of 47 newly diagnosed primary ITP patients with bleeding symptoms or risks, who received HD-DXM alone or in combination with rhIL-11, were retrospectively identified and systemically analyzed. These patients were divided into four groups according to their bleeding scale prior to initiation of treatment and therapeutic schedules, including monotherapy group (dexamethasone 40 mg/d on days 1-4) and combination therapy group [dexamethasone 40 mg/d on days 1-4 combined with rhIL-11 25 μg/(kg·d) on days 1-7] as well as high-risk group (bleeding scores≥5) and low-risk group (bleeding scores < 5). The clinical efficacy, onset time of response, duration of response, the platelet recovery level and treatment related toxicity profiles among different groups were systematically analyzed and compared.

    Results

    The platelet recovery level and duration of response in combination therapy group were more pronounced than those in monotherapy group [(97.38±49.18)×109/L vs (158.72±41.72)×109/L and (18.15±4.54) d vs (12.43±3.18) d, P < 0.01]. The rates of complete response (CR), response (R), no response (NR) and relapse as well as onset time of response showed no statistical difference between combination and monotherapy groups (P>0.05). Furthermore, the CR rate and platelet recovery level as well as duration of response in the ITP patients with high bleeding scores in combination therapy group was significantly higher than those in monotherapy group [37.50% vs 21.74%, (226.75±52.68)×109/L vs (166.72±39.28)×109/L and (18.45±4.48) d vs (11.84±3.73) d, P<0.01]. Meanwhile, the rates of R, NR and relapse as well as onset time of response in high bleeding scores patients were shown little difference between combination therapy and monotherapy group (P>0.05). The platelet recovery level as well as duration of response in ITP patients with low bleeding scores in combination group were significantly higher than those in monotherapy group [(184.36±44.50)×109/L vs (148.48±46.37)×109/L and (17.72±3.32) d vs (14.52±4.18) d, P<0.05]. In addition, the rates of CR, R, NR and relapse as well as onset time of response in ITP patients with low bleeding scores were shown little difference between combination and monotherapy group (P>0.05). Concerning treatment related toxicity profiles, no grade 3~4 toxicity occurred in patients of combination and monotherapy group.

    Conclusion

    HD-DXM combined with rhIL-11 is an effective and well tolerated therapeutic approach for the adult patients with newly diagnosed primary ITP. It can increase the platelet recovery level and improve response duration as well as clinical efficacies in the patients with high bleeding risk, which serves as a platform for the design of future prospective clinical trials.

  • Article
  • Hai-yuan-bo GUO , Huang-ming CAO , Wei HUANG , Xiao-lan YIN , Yin WU , Jun ZHOU
    doi: 10.13683/j.wph.2018.01.006
    Objective

    To observe the efficacy and safety of the Jiedu granule combined with transcatheter arterial chemoembolization (TACE) and gamma knife surgery on the hepatocellular carcinoma with portal vein tumor thrombus (PVTT).

    Methods

    Total 129 patients of hepatocellular carcinoma with PVTT were divided into trial group (n=66) and control group (n=63). TACE and gamma knife surgery were given to both groups, Jiedu granule (twice daily) was added to the trial group. The median survival time and cumulative survival rate were analyzed and the clinical adverse events were compared between two groups. The independent prognostic factors of patients were analyzed by Cox proportional hazard model.

    Results

    The 1-, 2- and 3-year cumulative survival rates were 45%, 23%, 17% in trial group and 21%, 10%, 8% in control group respectively. The median survival time was 0.7 and 5.4 months respectively. Survival analysis showed that the difference between the two groups was statistically significant (P<0.01). There were no significant differences in clinical adverse events between the two groups (P>0.05). The Cox proportional hazard model analysis showed that Child-Pugh classification was a risk factor for prognosis, while Jiedu granule was a protective factor.

    Conclusion

    Jiedu granule combined with TACE and gamma knife surgery can prolong the survival time of the hepatocellular carcinoma patients with PVTT, which is safe and well tolerated. The Jiedu granule is a protective factor to improve the prognosis of patients, and it can be widely used in clinic.

  • Article
  • Fang YAN , Yun-yun ZHENG , Wen-bo ZHANG , Yu-hui WANG
    doi: 10.13683/j.wph.2018.01.007
    Objective

    To evaluate the cerebrovascular reserve (CVR) capacity of acute ischemic stroke patients in middle cerebral artery (MCA) territory, and to analyze the correlation between CVR and neurological function improvement.

    Methods

    CT perfusion imaging (CTPI) was performed in 50 patients with acute ischemic stroke in MCA territory before and after 5% CO2 inhalation. The regions of interest (ROI) were selected in basal ganglia, corona radiata and semiovale center. The hemodynamics parameters, such as regional cerebral blood flow (rCBF), cerebral volume (CBV), mean transit time (MTT) and time to peak (TTP), were measured in ROI. Based on the contralateral normal controls, the changes of hemodynamics parameters of affected MCA territory were analyzed. The CVR of each MCA territory was calculated, and the association between the CVR on the affected side with the NIHSS score subtraction was investigated.

    Results

    Before the CO2 inhalation test, the lower mean rCBF (P<0.01), the slightly higher CBV (P<0.05), and the significantly prolonged MTT and TTP (P<0.01) on the affected side were found. After the CO2 inhalation test, according to the change of rCBF in the affected side, CVR was categorized into three types: increased rCBF (28 cases), no obvious change in rCBF (8 cases) and decreased rCBF (14 cases). There was a positive correlation between CVR on the affected side and NIHSS score subtraction on the 14th day (r=0.58, P<0.05).

    Conclusions

    In the affected side of ischemic stroke patients, the changes of cerebral perfusion in middle cerebral artery (MCA) territory can be found, and the CVR can be positively correlated with neurological function improvement.

  • Article
  • Wen-qi XU , Sheng WANG , Yi-an HUANG , Yan WANG , Qi-bing MEI , Li LIU
    doi: 10.13683/j.wph.2018.01.008
    Objective

    To compare the structural changes of gut microbiota in non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) in rats.

    Methods

    Thirty Wistar rats were randomized into three groups (0 rats each group): normal group, high-fat diet (HFD) group, Lieber-DeCarli liquid diet (LD) group. The NAFLD and ALD rat models were established by feeding HFD and LD, respectively. After six weeks, the changes of liver histopathology were assessed in all groups. Their stools were collected and the composition of gut microbiota was determined by Illumina MiSeq sequencing.

    Results

    HE staining showed obvious hepatic pathological change and ORO staining showed obvious hepatic fat deposition in HFD group and LD group. The diversity of gut microbiota in HFD group and LD group was significantly decreased compared to normal group (P<0.05 or P<0.01). The PCA showed obvious difference in microbial community structure among three groups. At phylum level, the relative abundance of Firmicutesin in LD group was increased compared to HFD group (P<0.05). At genus level, the relative abundance of Escherichia-Shigella and Rikenellaceae_RC9_gut_group was decreased while Ruminococcus_1 was increased in LD group compared to HFD group (P<0.05 or P<0.01). The LEfSe analysis showed that the Rikenellaceae, Fusobacteriaceae, Pasteurellaceae and Aerococcaceaewere were significantly enriched in HFD group compared to LD group. The Ruminococcaceae_NK4A214_group,Rikenellaceae_RC9_gut_gro up, Alistipes, Marvinbryantia, Fusobacterium, Papillibacter, Pasteurella, Anaerotruncus and Globicatella were the key phylotypes of HFD group while Ruminococcus_1, Lachnospiraceae_NK4A136_group and Alloprevotella were the key phylotypes of LD group.

    Conclusion

    The gut microbiota dysbiosis is present both in NAFLD and ALD in rats, but their gut microbiota is still different significantly.

  • Article
  • Chao SHI , Xing WANG , Hong-ling ZHU
    doi: 10.13683/j.wph.2018.01.009
    Objective

    To investigate the clinical efficacy and safety of the Xuezhikang capsule combined with fluvastatin sodium on hyperlipidemia.

    Methods

    A total of 124 patients with hyperlipidemia were randomly divided into the observation group and the control group, with 62 cases in each group. The control group was given fluvastatin sodium (40 mg/time, once daily), the observation group was additionally taken Xuezhikang capsule (0.6 g/time, twice daily), and the treatment time was 8 weeks. The serum lipid levels [total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and highdensity lipoprotein cholesterol (HDL-C)] and C reactive protein (CRP) levels] before and after 4 and 8 weeks treatment, and hemorheology indexes (high shear whole blood viscosity, low shear whole blood viscosity, plasma viscosity, hematocrit and fibrinogen) before and after treatment, and the efficacy and adverse drug reactions were observed and compared.

    Results

    The total effective rate of the observation group (85.48%) was higher than that of the control group (69.35%, P<0.05). Compared with before treatment, the serum TC, TG, LDL-C and the CRP after 4 and 8 weeks treatment of both two groups were decreased, and the HDL-C was increased (P<0.05). Compared with control group, the serum lipid level of observation group was improved more significantly (P<0.05). Compared with before treatment, the hemorheology indexes of two groups after treatment were decreased; the plasma viscosity, hematocrit and fibrinogen of observation group were lower than those of control group (P<0.05).

    Conclusion

    Xuezhikang capsule combined with fluvastatin sodium can obviously improve blood lipid levels and reduce CRP level in hyperlipidemia treatment.

  • Review
  • Tian MA , Qiang JIE , Wei LI , Teng SHEN
    doi: 10.13683/j.wph.2018.01.010

    Onychomycosis has affected lots of people, but its treatment remains difficult. Compared with the nail removal surgery and the oral therapy, the topical therapy gets more and more attention due to its localized effects, which results in minimal adverse systemic events and better compliance with non-invasive. This article discusses the factors of affecting drug permeation across the nail plate, and provides the transungual drug formulations and its technology including some commonly used transungual enhancers and the in-vitro models for transungual study as a reference for the research of transungual drug delivery.

  • Review
  • Gang ZHENG
    doi: 10.13683/j.wph.2018.01.011

    Atherosclerosis is the main cause of coronary heart disease, stroke and peripheral vascular disease. Its pathogenesis is complex and has not been fully elucidated at present. The drug therapy is one of the main treatments for atherosclerosis and its related cardiovascular diseases. The key to drug therapy is to discover the targets associated with atherosclerosis. This review summarizes the updated research progress on the targets of atherosclerosis and its related cardiovascular diseases.

  • Review
  • Fang WANG , Lu CAI , Feng-feng CAI , Zi-cheng YU
    doi: 10.13683/j.wph.2018.01.012

    The mevalonate pathway is a highly conserved metabolic approach, which provides vital isoprenoid building blocks for cell growth, such as prenyl pyrophosphates. Now increasing researchers believe that mevalonate pathway is associated with the hyperactivity of tumor cells, which is one of the important targets for cancer therapy. The upstream accumulation of intermediate and its downstream depletion in cells mevalonate pathway can lead to some cancers. Therefore, by immune surveillances, the mevalonate pathway can directly or indirectly influence tumor biology. This paper summarizes the anti-tumor mechanism of statins and bisphosphonates by blocking mevalonate pathway.

  • Review
  • Xiang LI , Ya-li WENG
    doi: 10.13683/j.wph.2018.01.013

    Primary liver cancer (PLC) is one of the most common malignancies in the world, of which the fatality rate is second of the cancer mortality. Hepatocellular carcinoma (HCC) is the most common PLC. Hepatitis B virus (HBV) infection is the most common cause of liver cancer. Research has shown that the risk factors of HBV related HCC mainly include host factors, virus factors and other factors. This review summarizes the association between HBV related HCC and its risk factors.

  • Review
  • Gui-yan WANG , Wei ZHANG , Wei YANG
    doi: 10.13683/j.wph.2018.01.014

    In the patients with chronic liver disease, their long-term liver damage results in a poor blood flow. However, the Huoxue Huayu method is commonly used in treatment. According to the guiding ideology of syndrome differentiation and treatment and combined with the characteristics of the disease in different periods, this paper describes the approach in promoting blood circulation through the combined use of Qingre Jiedu, Yiqi Fuzheng, and Shugan Liqi, which can achieve the goal of slowing disease progression and relieving symptoms.

  • Review
  • Shan MAO , Wei GU
    doi: 10.13683/j.wph.2018.01.0015

    This article describes the concept and connotation of chronic respiratory disease, and then analyzes the problems and characteristics of Chinese chronic respiratory disease management in depth. Combined with Chinese national conditions, this paper puts forward the construction of Chinese characteristics with chronic respiratory disease management model in aims to improve the prevention and treatment of chronic respiratory disease in China.

News